A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function.

Trial Profile

A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Oct 2014

At a glance

  • Drugs Anacetrapib (Primary)
  • Indications Atherosclerosis
  • Focus Pharmacokinetics
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 30 Apr 2014 Results published in the Journal of Clinical Pharmacology.
    • 07 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Jun 2011 Planned end date changed from 1 Jul 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top